iPS Cells & Regenerative Medicine– category –
-
Cellipont Bioservices Supports Six Cell Therapy Programs Towards 2026 IND Filings, Highlighting CDMO Market Growth
Cellipont Bioservices (via Contract Pharma news) USA Overview Texas-based cell therapy CDMO Cellipont Bioservices announced it is supporting six client projects anticipated to reach Investigational New Drug (IND) submission in 2026. Thei... -
Fate Therapeutics to Detail iPSC-Derived Cellular Immunotherapy Pipeline at Cantor Global Healthcare Conference
Fate Therapeutics Press Releases / Barchart.com USA Overview Fate Therapeutics announced its management will participate in a fireside chat at the Cantor Global Healthcare Conference in New York, September 9-12, 2026. The company plans t... -
Fate Therapeutics to Present Encore Clinical Data for iPSC-Derived FT819 in Systemic Scleroderma
Fate Therapeutics, Inc. Investors USA Overview Fate Therapeutics will re-present clinical data for FT819, its iPSC-derived, off-the-shelf CAR T-cell product candidate, at the CCR – West 2026 conference. The data potentially shows early c... -
CRISPR Therapeutics to Detail Pipeline Progress at Morgan Stanley Global Healthcare Conference
CRISPR Therapeutics Press Releases USA Overview CRISPR Therapeutics announced its management will participate in the Morgan Stanley 24th Global Healthcare Conference on September 10, 2026. This engagement provides a critical platform for... -
IV Exosome Therapy: Under Investigation for Cell Behavior Modulation and Anti-Inflammation, FDA Not Yet Approved
Sanger Wellness Center USA Overview Exosomes, tiny extracellular vesicles involved in intercellular communication, are being investigated for their potential to influence cell behavior, inflammatory pathways, tissue response, and recover... -
Nanjing Drum Tower Hospital Engineers Stem Cell Patch for Cardiac Regeneration: A New Frontier in Heart Failure Treatment
Nanjing Drum Tower Hospital China Overview Nanjing Drum Tower Hospital, in collaboration with a Korean lab, has achieved a significant breakthrough in stem cell-based heart regeneration. Their novel bioengineered cardiac patch, leveragin... -
BrainChild Bio Secures $116M, Earns FDA Breakthrough Designations for CAR-T Therapy Against Pediatric Brain Cancer DIPG
Hoodline USA Overview BrainChild Bio, a biotechnology firm spun out of Seattle Children's Hospital, has raised $116 million to advance its novel CAR-T cell therapy for Diffuse Intrinsic Pontine Glioma (DIPG), a devastating pediatric brai... -
Harro Höfliger’s Robust Database Optimizes Product Development, Resolving Regenerative Medicine Manufacturing Bottlenecks
Cell and Gene Germany Overview Harro Höfliger introduced a method for characterizing and optimizing product development in regenerative medicine manufacturing, leveraging a robust database. Integrated with a hierarchical automation platf... -
Exosome Therapy Revolutionizes Skin Treatment: Promotes Cell Regeneration and Anti-Inflammation Without Physical Injury
Dr Azra Vaziri USA Overview Exosome therapy harnesses tiny extracellular vesicles secreted by stem cells to deliver biological signals for cell repair and regeneration to skin cells. Unlike traditional dermapen or microneedling, this tre... -
The Next Frontier in Hematology: China’s Leadership in CAR-T and CRISPR Gene Editing
Source unknown China Overview China has rapidly emerged as a global leader in hematology, achieving significant breakthroughs in CAR-T cell therapy and CRISPR-based hematopoietic stem cell editing. This rapid ascent is profoundly reshapi...
